Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr

@article{Markman2001PhaseIT,
  title={Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr},
  author={Maurie Markman and Brian N. Bundy and David S. Alberts and Jeffrey M. Fowler and D. L. Clark-Pearson and Linda F. Carson and Scott S Wadler and Joshua Z. Sickel},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 4},
  pages={
          1001-7
        }
}
PURPOSE To compare the progression-free and overall survival in small-volume residual ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an experimental regimen of IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin. PATIENTS AND METHODS Patients were randomized to receive either IV paclitaxel 135 mg/m(2) over 24 hours followed by IV cisplatin 75 mg/m(2) every 3 weeks for six courses or IV carboplatin (area under curve 9) every 28 days for two… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 334 CITATIONS, ESTIMATED 35% COVERAGE

Ovarian cancer standard of care: are there real alternatives?

  • Chinese journal of cancer
  • 2015
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 10 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Intraperitoneal Cancer Therapy

VIEW 18 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
VIEW 7 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Counterpoint: Intraperitoneal chemotherapy: an investigational treatment in ovarian cancer.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2004
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1989
2019

CITATION STATISTICS

  • 20 Highly Influenced Citations

  • Averaged 15 Citations per year from 2017 through 2019